US5474547A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implanting devices for the focal release of neuroinhibitory compounds
Assignee: Brown University Research Foundation Inc
•
Filing: 1993-12-16
•
Granted: 1995-12-12
•
Expires: 2013-12-16
Abstract
Abstract Methods are disclosed for the alleviation of movement disorders via the implantation of static devices which focally release neuroinhibitory compounds to preselected brain areas. Pathological conditions to be treated by these methods include parkinsonian movement disorders, Huntington's chorea, and epileptiform seizure activity. In the treatment of parkinsonism, target areas implantation include the subthalamic nucleus, the globus pallidus internus, and the substantia nigra pars reticulata. In the treatment of epilepsy, implants may be placed in an epileptogenic focus area of neural over-activity. The devices may be polymeric implants that release neuroinhibitory compounds such as GABA, GABA agonists, GABA potentiators, action potential blockers and voltage dependent calcium channel blockers, and glutamate antagonists. Alternatively, the devices may contain living cells which secrete neuroinhibitory compounds.
Inventors
- 👤 Patrick Aebischer
- 👤 Patrick A. Tresco
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:08
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/022; A61K; A61K31/00; A61K31/13; A61K31/14; A61K31/185; A61K31/19; A61K31/195; A61K35/00; A61K35/12; A61K35/37; A61K35/39; A61K35/48; A61K35/54; A61K45/00; A61K45/06; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/0085; A61K9/0087; A61K9/0092; A61M; A61M31/00; A61M31/002; B; B01; B01J; B01J13/00; B01J13/02; C; C12; C12N; C12N11/00; C12N11/02; C12N11/04; C12N5/00; C12N5/0012; C12N5/06; C12N5/0602; C12N5/0613; C12N5/0614; C12N5/0618; C12N5/0619; C12N5/0676; A61F2250/00; A61F2250/0058; A61F2250/0067; A61K2035/126; A61M2210/00; A61M2210/06; A61M2210/0687; A61M2210/0693; C12N2533/00; C12N2533/30
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
127 words
A method for alleviating parkinsonian movement disorders in an individual having the same, comprising implanting a static device adjacent a brain area within the basal ganglia of said individual, said brain area selected from the group consisting of the subthalamic nucleus, globus pallidus internus, and substantia nigra pars reticulata, said device focally releasing at least one compound which acts to inhibit over-activity in at least one neuron within said brain area, said compound being selected from the group consisting of GABA, GABA agonists, GABA potentiators, action potential blockers, voltage dependent calcium channel blockers, glutamate antagonists, phenytoin, carbamezepine, valproate, barbiturates, benzodiazapines, ethosuximide, tetrodotoxin, saxitoxin, and conotoxins, said inhibition effecting the disruption of neural over-activity within said basal ganglia, said disruption effecting the alleviation of said parkinsonian movement disorders.
Claim 2
Independent Claim
127 words
A method for alleviating parkinsonian movement disorders in an individual having the same, comprising implanting a static device adjacent a brain area within the basal ganglia of said individual, said brain area selected from the group consisting of the subthalamic nucleus, globus pallidus internus, and substantia nigra pars reticulata, said device focally releasing at least one compound which acts to inhibit over-activity in at least one neuron within said brain area, said compound being selected from the group consisting of GABA, GABA agonists, GABA potentiators, action potential blockers, voltage dependent calcium channel blockers, glutamate antagonists, phenytoin, carbamezepine, valproate, barbiturates, benzodiazapines, ethosuximide, tetrodotoxin, saxitoxin, and conotoxins, said inhibition effecting the disruption of neural over-activity within said basal ganglia, said disruption effecting the alleviation of said parkinsonian movement disorders.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein said neuron receives functional presynaptic input.
Claim 4
Dependent Claim
17 words
The method of claim 1 wherein said compound is secreted from living cells contained within said device.
Claim 5
Dependent Claim
24 words
The method of claim 3 wherein said cells are selected from the group consisting of NIT cells, islet derived cells, and oviduct derived cells.
Claim 6
Dependent Claim
15 words
The method of claim 3 wherein said cells are genetically engineered to secrete said compound.
Claim 7
Dependent Claim
10 words
The method of claim 5 wherein said compound is omega-conotoxin.
Claim 8
Dependent Claim
25 words
The method of claim 1 wherein said movement disorders are associated with the loss of dopamine releasing neurons of the substantia nigra in Parkinson's disease.
Claim 9
Dependent Claim
10 words
The method of claim 1 wherein said compound is GABA.
Claim 10
Dependent Claim
20 words
The method of claim 1 wherein said brain area within the basal ganglia of said individual is the subthalamic nucleus.
References Cited (Backward Citations)
US4353888A
Cited
US4346112A
Cited
US5017375A
Cited
US4892538A
Cited
US5156844A
Cited
US5158881A
Cited
US5182111A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-12-11 | 1999-06-12 | 1999-12-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-12-11 | 2003-06-12 | 2003-12-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-12-11 | 2007-06-12 | 2007-12-12 | $7700.00 | Window Closed / Lapsed |